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certain type ofcells.  Diagnosis or therapy must be accurately prepared for and planned 
by medical professionals. The fast access to the internet has become a key tool for 
medical professionals to obtain this type of  information. A web page has been developed 
that links nuclear and biological data to radiopharmaceutical information.  Queries can be 
performed on this database to sort the radiopharmaceuticals by radiological half life, 
gamma energy, biological halflife, medical application, chemical information or other 
parameters. This capability allows medical professionals and scientists to select 
radiopharmaceuticals by their characteristics. There are approximately 100 medical 
isotopes in the database. 
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A WEB-BASED MEDICAL RADIONUCLIDE DATABASE 
1.  INTRODUCTION 
Radiopharmaceuticals are "radioactive materials that are used as a drug for 
diagnosis and therapy" (Saha, 1997).  There are two types ofradiopharmaceuticals: 
diagnostic and therapeutic. Diagnostic radiopharmaceuticals provide information 
about a particular disease by determining morphological or physiological information 
in patients suffering from a variety ofdiseases (FDA, 1999). Therapeutic 
radiopharmaceuticals deliver a particulate particle that is attached to a pharmaceutical to 
a target organ to kill tumorous cells. Physicians, nuclear pharmacists, medical physicists, 
health physicists and nuclear engineers use radiopharmaceuticals for administration, 
cancer treatment planning, detection ofcancer, prescribing doses to radiopharmaceutical 
and research. Most ofthe information on radiopharmaceuticals that are Food and Drug 
Administration (FDA) approved is published on insert packets submitted by the 
radiopharmaceutical manufacturer. The published insert packages are not easily accessed 
by patients, and updated information from the insert packets are not easily available for 
medical professionals to obtain.  The "Web-Based Medical Radionuclide Database" 
was developed so current information on these radiopharmaceuticals can be easily 
accessed on the web. 2 
1.1 Ideal Diagnostic Radiopharmaceuticals 
To determine if  a radiopharmaceutical is a diagnostic radiopharmaceutical, the 
FDA evaluates it by five different categories ( See Figure 1 ). The FDA evaluates 
diagnostic radiopharmaceuticals based on how well they provide accurate information on 
the patient's diagnosis, monitoring, or treatment. 
Figure 1 FDA Evaluation Factors For Diagnostic Radiopharmaceuticals 
1. 	 Structural localization, such as the delineation ofthe gastrointestinal tract or 
Enhancement of  the blood vessel. 
2. 	 Functional assessment of  an organ or body system, such as ejection fraction, 
myocardial wall motion or cerebral perfusion.  Functional assessment require a 
qualitative and quantitative understanding ofa parameter (the quantitative parameter 
needs not to be absolute) along with the confidence interval for that parameter in 
normal subjects. 
3. 	 Biochemical characterization: for example, analyzing the glucose utilization in the 
heart. Biochemical indications focus on determining ifthe measured parameter is 
within normal limits and requires a qualitative or quantitative understanding ofthe 
parameter (the quantitative parameter needs not to be absolute) along with the 
confidence interval for that parameter in normal subjects. 
4. 	 Disease/organ specific, such as the use of  a monoclonal antibody for the detection of 
a tumor subtype or the use of  labeled cells for the detection of  infection or thrombus. 
5. 	 Management decision making, such as the assessment ofpost revascularization 
outcome in patients with coronary artery disease, the respectability of  a patient with 
recurrent diseases, tissue viability, the prognosis of  the patient's disease or 
interventional outcome. 3 
There are many factors involved in selecting radiopharmaceuticals for imaging 
based on their nuclear and biochemical properties. Ideal diagnostic nuclear 
properties are based on decay and photon energy (Saha, 1993). Radionuclides have 
unstable nuclei that decay spontaneously by alpha particle (4He nucleus) emissions, beta 
particles (electron emission), positron (positive electron emission), electron capture and 
isomeric transition. 
Particle emission from alpha or beta decay are not used for diagnostic 
radionuclides. For diagnostic purposes alpha and beta particles will cause radiation 
damage to human tissues and give high radiation doses (Saha, 1993). Rather they are 
usually used for therapy to effectively deliver a dose to abnormal cells. 
Diagnostic radionuclides use isomeric transition and electron capture because 
they do not emit charged particles in the body that cause unwanted radiation-induced 
damage to the body (Katanic, 1997). 
The proper range of  photon energies for diagnostic imaging is important because 
enough energy is needed for detection by a nuclear medicine camera. The energies should 
range between 30 to 300 keY emitted gamma energy with 150 keY being an ideal energy 
(Saha, 1997). 
An ideal property for diagnostic radionuclide is that their photon energy spectrum 
be monoenergetic, i.e, emitting a photon at a single energy that is high enough to exit the 
body. Low energy photons are more readily attenuated in the body and hence cannot 
survive to interact with the detector crystal (Katanic, 1997). The photon energy should 
not be so high that the detector has a low efficiency at that energy. 4 
The radiological half life is very important in considering an ideal diagnostic 
radiopharmaceutical. Radiological halflife is the time required for half ofthe 
radionuclide to decay away. Radiological halflife is independent ofany physiochemical 
condition and is characteristic for a given radionuclide (Saha,1997). 
Patients who are administered radiopharmaceuticals eliminate them by urination, 
defecation or perspiration. Biological half life is the time it takes for the 
radiopharmaceutical to be removed biologically from the body. The overall biological 
disappearance ofa radiopharmaceutical from the body also depends on the radiological 
halflife.  An ideal radiological halflife should be between hours to a few days, and an 
ideal biological halflife should be comparable to the length ofthe diagnostic procedure, 
but not much longer, so the body can eliminate it to lessen the radiation dose to the 
patient (Saha, 1993). 
1.2 Ideal Therapeutic Radiopharmaceuticals 
Ideal therapeutic radiopharmaceuticals are beta or alpha emitters that deliver a 
dose to treat cancer tumors (Katanic, 1997). Their radiological half lives are days, weeks 
or months. Their energies have to be high enough to penetrate the tissue and deliver an 
effective dose in one administration.  Therapeutic radiopharmaceuticals must have ideal 
biochemical properties to make sure the radiopharmaceuticals are stable for a specific 
time to deliver a dose effectively.  They should be free of  impurities, be carrier free, have 
a very high target-to-non-target ratio, and a biological half life that is long enough to 
provide a therapeutic treatment to the target organ. 5 
1.3 Clinical Research 
Therapeutic and diagnostic radiopharmaceuticals having these characteristics 
provide information leading directly to a patient management decision. To evaluate 
clinical investigations ofdiagnostic or therapeutic radiopharmaceuticals several clinical 
trials are performed to test the specific indication. The clinical trial design is applicable to 
disease specific indications (Katanic, 1997). Radiopharmaceuticals are subject to the 
regulations ofthe Nuclear Regulatory Commission (NRC) and FDA (FDA, 1999). 
The NRC licenses physicians, hospitals and non-hospital-based physicians to 
administer radiopharmaceuticals.  When a health professional or scientist develops a new 
radiopharmaceutical, he or she must submit a claimed investigation exemption for a new 
drug to the FDA (Katanic, 1997). Most radiopharmaceuticals are administered to humans. 
Human investigations need a written consent, and an Institution Review Board oversees 
the investigations.  The investigation is carried out in three phases. 
1.4 Clinical Trials 
In phase I FDA trials, a limited number ofpatients participate in the study. The 
purpose ofphase I trials is to determine the drug's biodistribution, metabolism, excretion, 
toxicity, adverse reaction, and optimum dosage.  Phase II FDA trials involve a limited 
number ofpatients for a specific disease (Saba, 1997). Phase III FDA trials determine the 
drug's efficacy, safety, and the necessary dosage to treat or diagnose the disease (Saba, 
1997). 6 
When the investigation is complete, the supporting data are submitted to the FDA 
with the New Drug Application. Ifthe FDA approves the New Drug Application, the 
investigator may then market the drug with FDA restrictions. The FDA specifies the 
indications for use, route ofadministration, and any other details it feels necessary.  This 
information is given on the radiopharmaceutical package inserts. 
There are 46 predominately used radiopharmaceuticals that are currently 
approved by the FDA (See Tables 1 and 2). Currently there are more available 
radiopharmaceuticals that have similar medical applications and radiological 
characteristics than the 46 radiopharmaceuticals that are in Tables 1 and 2. They are not 
used as much because of  several factors, such as availability, cost, and replacement by 
improved isotopes that have better biochemical applications.  The common 
radiopharmaceuticals listed in Tables land 2 have more effective diagnosis or therapy 
capabilities because they have improved biochemical structures to the isotopes. For 
example, 99mTc are capable ofcombining with several different chemicals for imaging 
different organisms. Tablel shows the 99mTc FDA approved medical applications. 7 
Table 1. Common 99mTc FDA Approved Radiopharmaceuticals 
Radiopharmaceutical  Trade Name  Medical Application 
Tc-99m Arcitumomab  CEAScan  Monoclonal antibody for colorectal 
cancer 
Tc-99m Albumin Colloid  Microlite  Imaging of  RES (liver/spleen) 
Tc-99m Bicisate (ECO)  Neurolite  Cerebral perfusion imaging 
Tc-99m Oisofenin D1SIDA  Hepatolite  Hepatobiliary imaging 
Tc-99m Examet.'lzine (HMPAO)  Ceretec  Cerebral  perfusion imaging 
Tc-99m Glucept.'lte  Glucoscan  Renal imaging 
Tc-99m Human Serum Albumin  Imaging of  cardiac chambers 
Tc-99m Lidofenin (HIDA)  TeclUlescan (HIDA)  Hepatobiliary imaging 
Tc-99m Macroaggregated Albumin  Pulmolite; Macrotec  Pulmonary perfusion 
Tc-99m Mebrofenin  Choletec  Hepatobiliary imaging 
Tc-99m Medronate (MOP)  Bone imaging 
Tc-99m Mertiatide  TeclUlescan MAG3  Renal imaging 
Tc-99m P280  Acutech  Peptide for blood clot imaging 
Tc-99m Nofetumomab Merpcntan NR­
Ul-IO 
Verluma  Monoclonal antibody fab fragment for 
imaging small cell lung cancer 
Tc-99m Oxidronate (HOP)  Osteoscan HOP  Bone imaging 
Tc-99m Pentetate  Techneplex, Technescan OTPA  Renal imaging and function studies 
radioaerosol ventilation imaging 
Tc-99m Pyrophosphate (PYP)  Techneplex, Technescan OTP  A  Avid infarct imaging 
Tc-99m Sulfur Colloid  Cardiolite Miraluma  Imaging of  RES (liver/spleen), gastric 
emptying, GI bleeds 
Tc-99m Teboroxime  Cardiotec  Myocardial perfusion imaging 
Tc-99m Tetrofosmin  Myoview  Myocardial perfusion imaging 
Tc-99m Succimer (OMSA)  Cardiolite,  Miralullla  Renal imaging 
(DAMS, 1997) 
A broad range of  non 99mTcradiopharmaceuticais are also used and FDA 
approved. They are primarily used to determine metabolism, labeling, imaging, uptake 
and perfusion (See Table 2). 8 
Table 2 Common Non 99mTc Radiopharmaceuticals 
Radiophannaceutkal  Trade Name  Medical Application 
Co-57 Cyanocobalamin  Rubratope, Dicopac  Schilling Test 
Co-58 Cyanocobalamin  Dicopac  Schilling Test 
Cr-51  Sodium Chromate  Chromotope  Labeling RBC's 
Ga-67  Neoscan  Soft tissue tumor and inflammatory 
process imaging 
F-18 FDG  Positron emission tomography imaging 
In-11 I Chloride  Indiclor  For labeling monoclonal antibodies and 
~~~ides  Oncoscint & Octreoscan 
In-III Pentetate  Imaging ofCSF kinetics 
In-11 I Oxyquinoline (thine)  Labeling leukocytes 
In-III Capromab Pendetide  Prost.1Scint  Monoclonal antibody for imaging 
prostate cancer 
In-III Imciromab Pentetate  Myoscint  Monoclonal antibody for diagnosis of 
heart necrosis 
In-III Pentetreotide  Octreoscan  Imaging of  neuroendocrine tumors 
In-11 I satumomab pendetide  OncoScint CR/OV  Imaging ofmetastatic disease associated 
with colorectal and ovarian cancer 
1-123 Sodium Iodide  Thyroid imaging and uptake 
1-125lothalamate  Glofil  Measurement ofglomerular filtration 
1-125 Human Semm Abumin  Isojex  Plasma volume determinations 
1-131  Sodium Iodide  Thyroid uptake, imaging and therapy 
1-131  lodomethylnorcholeskrol  Adrenal imaging 
1-131  Metaiodobenzylquanidine  1-131  MIBG  Imaging of  pheochromocytomas and 
neuroblastomas 
Kr-81m Gas  Pulmonary ventilation imaging 
P-32 Chromic Phosphate  Phosphocol  P32  Therapy ofintracavitary malignancies 
P-32 Sodium Phosphate  Therapy of  polycythemia vera 
Rb-82  Cardio-Gen-82  Positron emission tomography imaging 
Sm-153 Lexidronam  Quadramet  Palliati ve treatment of  bone pain of 
skeletal metastases 
Th-201  Myocardial perfusion imaging, 
parathyroid and tumor imaging 
(UAMS, 1997) 
9 
The purpose ofthese radiopharmaceutical tables was to develop a database that 
lists all the FDA-approved radiopharmaceuticals by providing (1) up to date descriptions 
ofthe FDA approved radiopharmaceuticals and (2) clinical uses ofall diagnostic and 
therapeutic radiopharmaceuticals, their biological half  lives, and radiological information 
for all the radiopharmaceuticals. 10 
2. PROJECT DEFINITION 

This project involved developing a list ofeach radiopharmaceutical's 
characteristics that provide information to medical professionals to make choices in 
selecting radiopharmaceuticals for patient imaging and therapy. Medical professionals 
have to choose radiopharmaceuticals that are capable ofworking with nuclear medicine 
instrumentation. Nuclear medicine instrumentation is very sensitive and requires a 
specific energy to image specific organs and to be able to trace the biodistribution ofthe 
radiopharmaceutical in the body for physiological studies to target organs (Saha, 1993). 
The radiopharmaceutical activity affects the duration ofimaging for the gamma camera 
to detect the radiation (Katanic, 1997). 
Therapeutic radiopharmaceuticals must localize in the target organ under study to 
provide safe efficacy in the treatment ofdisease with little localization to the non-target 
areas to prevent unnecessary radiation doses to the patient (Saba, 1993).  With these 
properties defined, a web-based database has been developed. The database contains the 
following set ofdata for each radiopharmaceutical: 
Atomic number (Z) 

Atomic mass number  (A) 

Element name 

Radiological half life 

Intrinsic specific activity 

Description ofradiopharmaceutical 

Chemical solution ofradiopharmaceutical 

Biological half life 

Decay mode 

Gamma ray energies 

Gamma ray intensities 

Medical application 
11 
The web-based database has the capability, for example, to find all 
radiopharmaceuticals that have beta energies with radiological halflives between 6 hours 
and 1 day and have gamma ray energies between 100 and 200 ke  V.  The web page output 
lists the isotopes, halflife, beta energies, intensities, beta decay, and medical applications 
ofthe selected radiopharmaceuticals. 12 
3. MATERIALS AND METHODS 
In order to develop the web page, a considerable amount ofresearch was done. 
The radiological information was taken from Browne and Firestone (1986). 
Much of  the pharmaceutical information was taken from the radiopharmaceutical 
packet inserts that accompany the radiopharmaceuticals and are published by several 
radiopharmaceutical companies in the United States.  From this information a database 
of  all the FDA-approved radiopharmaceuticals was composed. The web sites ofthe 
radiopharmaceutical manufacturers (Amersham, Bracco Diagnostics, Cytogen, Dupont 
Pharma, Immunomedics, Mallinckrodt Medical and Squibb Diagnostics) which produce 
FDA-approved radiopharmaceutical products contain this information. Insert packets 
were requested by contacting the radiopharmaceutical companies. 
The information was integrated into a database using Microsoft Windows Access 
97.  Access has the capability to develop many interconnected tables that can be queried. 
Each property ofeach radiopharmaceutical was developed into forms. For example, as 
seen in Figure 2, Assays, Chemicals, Elements and Facilities forms are connected to 
subforms that relate properties to these four forms. Each listed form interconnects with 
each property. Figure 2 lists the forms by their specific function. 13 
Figure 2 List of  Forms in Access Database 
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Each form was created into a switchboard select-down menu to add and edit data 
easily.  The editable parameters are listed as elements and basic isotope data, isotopes, 
organs, bodily parts, procedures, assays, chemicals and solutions, production, usage 
facilities and references (See Figure 3). 14 
Figure 3 Medical Isotope Database 
All the radiopharmaceuticals have developed tables in all the forms listed in 
Figure 3. One example using one radiopharmaceutical will be explained here which is 
representative ofall the radiopharmaceuticals researched. 
Ifthe Elements and basic isotope data form is selected, it will show the elemental 
information for each element that is listed as an FDA-approved radiopharmaceutical. The 
parameters included in this section are the element's symbol, atomic number, atomic 
weight, chemical name, phase of  matter, chemical group, electronic shell, specific 
activity, isotopic abundance, radiological half life and reference. Each table under this 15 
element information will list its separate information for each isotope including the 
element information (See Figure 4). In this specific example 13N elemental information is 
shown. 
Figure 4 Elements and Basic Isotope Data 
Figure 5 shows one table from the specific isotopic data for Decay Mode. The 
specific isotopic data lists specific information about each isotope that is used as a 
radiopharmaceutical.  The table includes queries on the element, radiological half1ife and 
isotope symbols with their atomic number. All ofthese data were taken from one source 
(Browne and Firestone, 1986). The isotope tables also include isotope decay modes, and 16 
alpha, beta, and gamma decay energies.  Figure 5 shows the top button on the right side is 
highlighted.  This example shows the decay mode for 13N. 
Figure 5 Specific Isotope Data For Decay Mode 
Figure 6 shows what alpha emitter input information would be like. On the right 
hand side ofthe menu the Alpha Energies button is highlighted. 17 
Figure 6 Specific Isotopic Data For Alpha Emitters 
Figure 7 lists an example ofan isotope that is a beta emitter. 18F emits a 635 keY 
maximum beta particle. The "Beta Energies" button is highlighted, which shows all the 
beta energies for 18F. 18 
Figure 7 Specific Isotopic Data for Beta Emitters 
Figure 8 shows a Specific Isotopic Data form for gamma energies. The "Gamma 
Energies" button is highlighted to show all the gamma energies for 13N and associated 
decay intensities. The decay intensities are the percentages that the isotope decays at this 
energy. For example,  13N decays at 511  keY 100 % of  the time. 19 
Figure 8 Specific Isotopic Data for Gamma Energy 
~ ",..,  • •  0/. Ace...  . II"""". D  ••• For"l  SQ[l 
Figure 9 shows an example of  the production reactions for I3N. There are six 
reactions that are listed.  Alpha-neutron (a,n), deuteron-alpha (d,a), proton-neutron (p,n), 
proton-gamma (p,y) and proton-alpha  (p,a) reactions can produce 13N. 20 
Figure 9 Specific Isotopic Data for Production Reactions 
The chemical and solutions table gives a brief chemical description ofthe 
radiopharmaceuticals and their chemical solutions. For example, Figure 10 shows 57CO 
Cyanocobalamin. Its description explains how the radiopharmaceutical is prepared and 
the chemical content of  the pharmaceutical. The solution ofthe pharmaceutical is listed 
with the chemical content. Below this information the medical applications ofthe 
radiopharmaceutical are listed. The medical procedure, targeted organ or disease and 
description is listed for each medical application. For example, the medical applications 
for 57 Co Cyanocobalamin are the detection of  pernicious anemia patients (See Figure 
10). 21 
Figure 10 Chemical and Solutions 
Figure 11  shows information about the administered dose to a patient and the 
bioaccumulation in the body. One way of  measuring how long the body bioaccumulates a 
radiopharmaceutical and eliminates it from target organs is by measuring its biological 
halflife. The biological half life for all FDA approved radiopharmaceutical has been 
clinically measured. The physician and medical physicist can calculate the dose a patient 
will receive during the period between the administration and the time the dose decreases 
to background levels.-Figure 11  shows 
57 Co biological half lives. The biological half 22 
lives listed show only measurements for target organs (organ of  interest) and major 
organs that eliminate radiopharmaceuticals from the body. 
Figure 11 Biological Half Life 23 
4. WEB PAGE 
The web page was designed and developed by individuals at the Northwest 
Alliance For Computational Science and Engineering (NACSE). They used the 
HyperSQL program which provides software interface that makes web browsers and 
SQL databases work together. HyperSQL is a tool constructing web-based query 
interface to SQL databases. The HyperSQL program provides an easy way to select 
queries from menus using a database program and to compose queries by filling out 
forms. The results ofa query are formatted as a hypertext to create links to the web page 
ofinterest and other web pages. 
The NACSE web administrators used the Microsoft Access database and 
integrated it into a web-based database. The current web address is found at 
http://www.nacse.org/cgi-bin/qmI2.0Itesting/radiopharm.qml. The title ofthe web page is 
"Medical Nuclide Database."  On the left side ofthe main web page are several links 
related to nuclear medicine and cancer information (See Figure 12). 
The web page otTers an easy, user friendly method to search by 
radiopharmaceutical chemicals, elements, radiological half life, decay mode, beta energy 
and gamma energies. 
If  a user wants to know about one particular radiopharmaceutical, that 
radiopharmaceutical can be clicked.  The output information lists the radionuclide's 
chemical name, radiological half life, decay mode, branching fraction, photon energies 
and intensities, production reactions, and medical applications (See Figure 12). 24 
Figure 12 Medical Radionuclide Web Page 
The "Chemical"search query on the left list all the radiopharmaceuticals by 
chemical name. This produces complete information on each radiopharmaceutical. The 
user clicks on one radiopharmaceutical, for example, SICr Sodium Chromate, by 
highlighting the SICr Sodium Chromate for entry.  SICr Sodium Chromate result 
information will be shown (See Figure 13). ------------ - - - -
25 
Figure 13 SlCr Sodium Chromate Information 
IV[euical Nudide Datalmsc 
The results for 51Cr in this case is linked to its radionuclide information. The 
radionuclide results include element name, chemical symbol, atomic number, atomic 
weight, phase, group and electron shell (See Figure 14). 26 
Figure 14 Radionuclide Information 
l\1edical Nuclide Dutubase 
SJlllhol  Cr 
Atomic II  24 
Wei&\tt  51.99 
Phase  Solid 
Group  Transition Metal 
Shen  Is2-2s2-2p6-3s2-3p6-4s2-3d4 
The output information for Chemical shows two links, chemical and medical 
application. The chemical output is linked to a separate page that lists and describes the 
chemical information about the specific radiopharmaceutical. For example, Figure 15 
shows a complete chemical description of
sl Cr Sodium Chromate. 27 
Figure 15 Chemical and Solution 
l\1edical NuclidE' Database 
Destription 	 Chromitope Sodium Chromate -51  diagnostic radiopharmaceutical for 
inlraVeTlOUS admirJistralion. The Agent provides radioactive Cr-51  in 
the form of sterile, nonpyro!!"nic,aqueouss solution of sodium 
cbromall!. Chemical Cornposilion Citric Acid, nextrose Anhydrous, 
Sodium Citrate, Water, clear, colorle" liquid in a 100 ml glass via\ 
The medical application link lists the usage and indications ofthe 
radiopharmaceutical.  SICr  Sodium Chromate is used for labeling red blood cells and 
imaging the spleen (See Figure 16). 28 
Figure 16 Medical Application 
l\'Iedical Nuclide ])atabase 
The purpose ofthe Decay Mode selection is to determine which nuclides decay 

by electron capture, isomeric transition or beta-minus decay. For example, Figure 17 

shows a portion ofthe radiopharmaceuticals that decay by beta-minus emission. 
29 
Figure 17 Beta Minus Decay (Partial List) 
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':;~ ::~::::::::::::;::~~~~~~~xm.'  j 
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The electron capture query is selected to find all the radiopharmaceuticals that 
decay by electron capture.  A partial list ofradionuclides that decay by electron capture is 
shown in Figure 18. The chemical form corresponding to the radionuclides are also 
shown. 30 
Table 18 Radiopharmaceutical Decay By Electron Capture (Partial List) 
Similarly Figure 19 shows a portion of  the radiopharmaceuticals that decay by 
isomeric transition. -----------------------------------------------
31 
-
Figure 19 Radiopharmaceutical Decay By Isomeric Transition (Partial List) 
The half life query is set up for the user to find the radiopharmaceuticals with half 
lives between some minimum and maximum halflife (See Figure 20).  For example, the 
only radiopharmaceutical that has a half life between 5 and 10 minutes is 13N Ammonia. 32 
Figure 20 Half life Query 
~tedical Nuclide ])atabase 
The beta energy query allows users to find out which radionuclides have beta 
energies within a certain range.  For example, the radiopharmaceuticals with maximum 
beta energies between 1 keVand 6 keY are shown in Figure 21. 33 
Figure 21  Beta Energy Query 
Users can also find radiopharmaceuticals with gamma energies between a lower 
and upper limit. For example, radionuclides with gamma energies between 5 and 10 keY 
are 
shown in Figure 22. Also shown for these radionuclides are other gamma energies of 
those radionuclides that are not in the search range. 34 
Figure 22 Gamma Energy Query 35 
5. CONCLUSIONS 
This project consisted ofthe development of  a medical radionuclide database. 
This database was developed for easy web-based access to the expanding research and 
development ofradio  pharmaceuticals. One ofthe most widely used applications for 
radiation is nuclear medicine, due to the distinct properties ofradiopharmaceuticals. The 
field of  nuclear medicine is growing at an astonishing rate. The medical radionuclide 
database will serve to provide information about radiopharmaceuticals and the capability 
for a user to access up six different queries on radiopharmaceuticals. 
In light ofthis accomplishment, recommendations for further development ofthis 
medical radionuclide database are suggested. Further research and development ofthe 
database can significantly implement more information about the radiopharmaceutical's 
capabilities. Radiopharmaceutical medical application and information on the 
biodistribution in the body are important to the medical professional to make decisions 
for planning medical treatment. 
More research in defining radiopharmaceutical medical applications would be 
helpful. The medical application information for radiopharmaceuticals needs to 
distinguish the specific organ of interest, tumor type, detection purpose, explanation of 
the radiopharmaceutical test results or scan detection indications, clinical pharmacology, 
and be able to calculate doses to patients administered radiopharmaceuticals until they 
reach background. This information will also inform patients and the public about the 
nuclear medicine procedures.  Public information about radiopharmaceuticals and their 
procedures should be available for general public interest.  A list ofthe 36 
radiopharmaceutical manufacturers is needed, so patients can obtain information about 
the radiopharmaceuticals so they are aware ofthe procedures. 
A large area ofresearch today is clinical therapeutic uses ofradiopharmaceuticals. 
Unfortunately there are only a few therapeutic radiopharmaceuticals that are FDA­
approved. There are approximately 100 clinical trials that are in the process ofseeking 
FDA approval. Because cancer rates are increasing, administration of 
radiopharmaceuticals is one cancer treatment option that is growing rapidly. A suggested 
list ofthe clinical trials would be helpful for patients and physicians to be informed ofthe 
current research in clinical radiopharmaceuticals and to be able to contact medical 
professionals involved with those clinical trials. 
Although more research and development is needed, the comprehensive medical 
radionuclide database established a foundation for continued development ofinformation 
about the rapid growth ofresearch in the field of  nuclear medicine. 37 
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Appendix: Radiopharmaceutical Manufacturer Contacts 
The list below is a reference of  all the FDA approved radiopharmaceuticals. The 
list contains the radiopharmaceutical manufacturer, title ofthe radiopharmaceutical insert 
packet and contact address. 
Amersham. DMSA Kit for the Preparation ofTechnetium Tc-99m Succimer Injection. 

July 1993 

2636 South Clearbrook Drive, Arlington Heights, IL 60005-4626 

1(800) 323-0668; 1 (708) 593-8236 (Fax) 

Amersham. CERETEC Kit for the preparation of  Technetium-99m Exametazine 

Injection.  1998 

2636 South Clearbrook Drive, Arlington Heights, IL 60005-4626 

1(800) 323-0668; 1 (708) 593-8236 (Fax) 

Bracco Diagnostics. CHROMITOPE Sodium Chromate Injection USP. 

October 1994 

P.O. Box 5225 
Princeton, NJ 08543 
(800) 631-3826 
(201) 825-1336 
Bracco Diagnostics. RUBRATOPE-57 Diagnsotic Kit Cyanocobalamin Co-57 

Diagnostic Kit. 

November 1997.. 

P.O. Box 5225 
Princeton, NJ 08543 
(800) 631-3826 
(201) 825-1336 
Bracco Diagnostics. IODOTOPE Sodium Iodide 1-131  Capsules USP. 
April 1998. 
P.O. Box 5225 
Princeton, NJ 08543 
(800) 631-3826 
(201) 825-1336 40 
Bracco Diagnostics. CARDIOGEN-82 Rubidium Rb 82 Generator. 
September 1985 
P.O. Box 5225 
Princeton, NJ 08543 
(800) 631-3826 
(201) 825-1336 
Bracco Diagnostics. MACROTEC Kit for the preparation of  Technetium Tc-99m 

Albumin Aggregated. 

December 1997. 

P.O. Box 5225 
Princeton, NJ 08543 
(800) 631-3826 
(201) 825-1336 
Bracco Diagnostics. MDP-BRACCO Kit for the preparation ofTechnetium Tc-99m 

Medronate. 

November 1997. 

P.O. Box 5225 
Princeton, NJ 08543 
(800) 631-3826 
(201) 825-1336 
Bracco Diagnostic. CHOLETEC Kit for the preparation ofTechnetium Tc-99m 

Mebrofin. 

November 1997. 

P.O. Box 5225 
Princeton, NJ 08543 
(800) 631-3826 
(201) 825-1336 
Bracco Diagnostic. TECHNEPLEX Kit for the preparation ofTechnetium Tc-99m 

Pentetate Injection. 

December 1997. 

P.O. Box 5225 
Princeton, NJ 08543 
(800) 631-3826 
(201) 825-1336 
Bracco Diagnostics. PHOSPHOTEC Kit for the preparation ofTechnetium Tc-99m 

Pyrophosphate. 

December 1997. 

P.O. Box 5225 
Princeton, NJ 08543 
(800) 631-3826 
(201) 825-1336 41 
CIS Bio International. Sodium Iodide 1-131  Solution For Oral Therapeutic Use. 
1987 
10 DeAngelo Drive 
Bedford, MA 01703-2204 
Cytogen. ProstaScint Indium-Ill Capromab Pendetide 
1998. 
http://www.cytogen.com 
Cytogen. Samarian-153-Lexidronam (QUADRAMET) For the Treatment ofPainful 
Malignant Osseous Lesions In Pediatric Patients. 
http://www.cytogen.com 
Du Pont Gallium-67 Citrate Information Packet. 
1996 
EAD, NA-228 
Wilmington, DE 19898-0001 
(800) 888-7704 
(302) 774-7321 
Du Pont PULMOLITE Kit for the preparation ofTechnetium Tc-99m Albumin 
Aggregated. 
1996 
EAD, NA-228 
Wilmington, DE 19898-0001 
(800) 888-7704 
(302) 774-7321 
Du Pont. MICROLITE Kit for the preparation ofTechnetium-99m Albumin Colloid. 

November 1991. 

EAD, NA-228 

Wilmington, DE 19898-0001 

(800) 888-7704 
(302) 774-7321 
Du Pont. NEUROLITE Kit for the preparation of  Technetium-99m Bicisate Injection 
November 17, 1994. 
EAD, NA-228 
Wilmington, DE 19898-0001 
(800) 888-7704 
(302) 774-7321 42 
Du Pont. REPATOLlTE Kit for the preparation ofTc-99m Disofenin. 

1990. 

EAD, NA-228 

Wilmington, DE 19898-0001 

(800) 888-7704 
(302) 774-7321 
Du Pont. VERLUMA Kit for the preparation ofTechnetium-99m Nofetumomab 
Merpentan. 
August 1996. 
EAD, NA-228 
Wilmington, DE 19898-0001 
(800) 888-7704 
(302) 774-7321 
Du Pont. PYROLITE Kit for the preparation of  Technetium Tc-99m Sodium Pyro and 
Trimeta Phosphates. 
November 1991. 
EAD, NA-228 
Wilmington, DE 19898-0001 
(800) 888-7704 
(302) 774-7321 
Du Pont. MIRALUMA Kit For the preparation ofTechnetium-99m Sestamibi 
January 1997. 
EAD, NA-228 
Wilmington, DE 19898-0001 
(800) 888-7704 
(302) 774-7321 
Immunomedics, Inc.  CEA-SCAN Technetium-99m Arcitumomab. 

1996. 

300 American Road 

Morris Plains, NJ 07950 

(888) 605-8200 
(973) 605-8282 (Fax) 
http://www.immunomedics.com 
Mallinckrodt. Sodium Chromate Cr-51  Injection. 

June 1997. 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 43 
Mallinckrodt. Gallium Citrate Ga-67 Injection. 

July 1995 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Mallinckrodt. Sodium Iodide 1-123 Capsules. 

July 1995 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Mallinckrodt. Iodinated 1-125 Albumin Injection. 

March 1996 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Mallinckrodt. Hippuran 1-131  Injection. 

July 1995. 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Mallinckrodt. Sodium Iodide 1-131  Capsules Diagnostics. 

July 1995. 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Mallinckrodt. Sodium Iodide 1-131  Capsules. 

July 1993. 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 44 
Mallinckrodt. Sodium Iodide 1-131  Solution. 

November 1995. 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Mallinckrodt. Indium In-Ill Chloride Sterile. 

July 1996 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Mallinckrodt. Octreoscan Kit for the preparation ofIndium In-Ill Pentetreotide. 

August 1994 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Mallinckrodt. Phosphocol P-32 Chromic Phosphate P-32 Suspension. 

January 1997. 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Mallinckrodt. Sodium Phosphate P-32 Solution. 

July 1995. 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Mallinckrodt. Technescan MAA Kit for the preparation ofTechnetium-99m Tc-99m 

Albumin Aggregated. 

July 1995. 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 45 
Mallinckrodt. TechneScan MAG3 Kit for the preparation ofTechnetium Tc-99m 

Mertiatide. 

March 1995. 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Mallinckrodt. TechneScan HOP Kit for the preparation ofTechnetium Tc-99m 
Oxidronate 
August 1996. 
675 McDonnell Blvd. 
St. Louis, MO 63042 
(800) 325-3688 
(314) 895-2377 
Mallinckrodt. TechneScan DTPA Kit for the preparation ofTechnetium Tc-99m 

Pentetate. 

April 1992. 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Mallinckrodt. Ultratag RBC Kit for the preparation ofTechnetium-99m Labeled Red 

Blood Cells. 

February 1992. 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Mallinckrodt. TechneScan Sulfur Colloid Kit for the preparation ofTechnetium Tc-99m 

Sulfur Colloid. 

July 1993. 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Mallinckrodt. Xenon Xe-133 Gas. 

July 1995. 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 46 
Mallinckrodt. Thallous Chloride TI 201  Injection. 

July 1995. 

675 McDonnell Blvd. 

St. Louis, MO 63042 

(800) 325-3688 
(314) 895-2377 
Medi+Physics. Dicopac Kit Oral Cyanocobalamin Co-57, Co-58. 

June 1995. 

2636 South Clearbrook Drive, Arlington Heights, IL 60005-4626 

1(800) 323-0668; 1 (708) 593-8236 (Fax) 

Nycomed Amersham. Indium-Oxine In-Ill Oxyquinoline. 

1997 

2636 South Clearbrook Drive, Arlington Heights, IL 60005-4626 

1(800) 323-0668; 1 (708) 593-8236 (Fax) 

Nycomed Amersham. Technetium Tc-99m Exametazime Injection. 

1997. 

2636 South Clearbrook Drive, Arlington Heights, IL 60005-4626 

1(800) 323-0668; 1 (708) 593-8236 (Fax) 

Nycomed Amersham. MET  ASTRON Strontium-89 Chloride Injection. 

1997 

2636 South Clearbrook Drive, Arlington Heights, IL 60005-4626 

1(800) 323-0668; I (708) 593-8236 (Fax) 

Nycomed Amersham. Myoview Technetium Tc-99m Tetrofosmin For Injection. 

1997. 

2636 South Clearbrook Drive, Arlington Heights, IL 60005-4626 

1(800) 323-0668; 1 (708) 593-8236 (Fax) 

P.E.T. N.E.T. Pharmaceuticals.  FDG Product Information. 
http://www.petnetpharmaceutical.com 
Squibb Diagnostics. MDP Squibb Kit for the preparation ofTechnetium Tc-99m 

Medronate. 

1996. 

http://www.squibb.com 

Squibb Diagnostics. CHOLETEC Kit for the preparation ofTechnetium Tc-99m 

Mebrofenin. 

1996. 

http://www.squibb.com 
